Shares of Keryx (NASDAQ: KERX ) got a boost on Thursday thanks to the decision-makers in the halls of Congress. The "Doc Fix" Medicare legislation, which just passed the House of Representatives, included language that exempts end-stage renal disease drugs from the reduced payment bundle until 2024, instead of 2016. This directly affects Keryx's lead drug candidate Zerenex, which removes extra phosphorous from patients on dialysis.
In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass dig into what the legislation means for the company, what the potential is for Zerenex, and what to watch for on June 7, when the FDA makes its approval decision.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.